Display Settings:

Format

Send to:

Choose Destination
    Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):554-8.

    Outcomes of children with favorable histology wilms tumor and peritoneal implants treated in National Wilms Tumor Studies-4 and -5.

    Source

    Department of Radiation Oncology, Northwestern University, Chicago, IL, USA. j-kalapurakal@northwestern.edu

    Abstract

    PURPOSE:

    There are no published reports on the optimal management and survival rates of children with Wilms tumor (WT) and peritoneal implants (PIs).

    METHODS AND MATERIALS:

    Among favorable histology WT patients enrolled in the National Wilms Tumor Study (NWTS)-4 and NWTS-5, 57 children had PIs at the time of nephrectomy. The median age was 3 years 5 months (range, 3 months to 14 years). The majority of children (42 of 57 [74%)] had Stage III tumors; 15 had Stage IV disease. All patients received multimodality therapy. Of 56 children who underwent primary surgery, 48 (84%) had gross total resection of all tumors. All patients received 3-drug chemotherapy with vincristine, dactinomycin, and doxorubicin. Whole-abdomen radiotherapy (RT) was used in 47 patients (82%), and in 50 patients (88%) the RT dose was 10.5 Gy.

    RESULTS:

    After a median follow-up of 7.5 years, the overall abdominal and systemic tumor control rates were 97% and 93%, respectively. A comparative analysis between children with PIs and those without PIs showed no significant differences in the clinical characteristics between the two groups. The 5-year event-free survival rates with and without PIs were 90% (95% confidence interval, 78-96%) and 83% (95% confidence interval, 81-85%) respectively (p = 0.20).

    CONCLUSIONS:

    Multimodality therapy with surgery, whole-abdomen RT, and three-drug chemotherapy delivered according to the NWTS-4 and -5 protocols resulted in excellent abdominal and systemic tumor control rates. All children should be monitored in long-term surveillance programs for the early detection and management of therapy-related toxicities.

    Copyright 2010 Elsevier Inc. All rights reserved.

    PMID:
    20457352
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2868597
    Free PMC Article

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk